Schroder Investment Management Group Has $17.37 Million Position in Repligen Co. (RGEN)

Schroder Investment Management Group cut its position in Repligen Co. (NASDAQ:RGEN) by 4.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 460,891 shares of the biotechnology company’s stock after selling 22,333 shares during the quarter. Schroder Investment Management Group owned about 1.35% of Repligen worth $17,371,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Eaton Vance Management bought a new position in shares of Repligen in the second quarter valued at $529,000. Jennison Associates LLC bought a new position in shares of Repligen in the second quarter valued at $291,000. PNC Financial Services Group Inc. grew its stake in shares of Repligen by 162.8% in the second quarter. PNC Financial Services Group Inc. now owns 5,635 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 3,491 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Repligen by 15.3% in the second quarter. Legal & General Group Plc now owns 68,677 shares of the biotechnology company’s stock valued at $2,845,000 after buying an additional 9,121 shares in the last quarter. Finally, NBW Capital LLC grew its stake in shares of Repligen by 93.8% in the second quarter. NBW Capital LLC now owns 43,909 shares of the biotechnology company’s stock valued at $1,820,000 after buying an additional 21,254 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Repligen Co. (NASDAQ RGEN) opened at $35.10 on Wednesday. Repligen Co. has a 52-week low of $28.48 and a 52-week high of $46.81. The company has a market cap of $1,496.03, a price-to-earnings ratio of 59.21, a price-to-earnings-growth ratio of 2.24 and a beta of 1.04.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, topping the Zacks’ consensus estimate of $0.11 by $0.04. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The firm had revenue of $36.58 million during the quarter, compared to analysts’ expectations of $35.69 million. During the same period in the previous year, the business posted $0.08 earnings per share. The company’s revenue for the quarter was up 48.2% compared to the same quarter last year. equities analysts predict that Repligen Co. will post 0.61 EPS for the current fiscal year.

A number of equities analysts have commented on the stock. TheStreet cut shares of Repligen from a “b-” rating to a “c” rating in a research report on Monday, November 13th. Zacks Investment Research cut shares of Repligen from a “buy” rating to a “hold” rating in a research report on Friday, August 18th. CL King assumed coverage on shares of Repligen in a research report on Monday, November 13th. They set a “buy” rating and a $41.00 price objective for the company. Jefferies Group reaffirmed a “hold” rating and set a $40.00 price objective on shares of Repligen in a research report on Thursday, October 19th. Finally, First Analysis raised shares of Repligen from an “equal weight” rating to an “overweight” rating and set a $47.00 price objective for the company in a research report on Monday, October 2nd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Repligen presently has a consensus rating of “Buy” and a consensus price target of $44.29.

TRADEMARK VIOLATION WARNING: “Schroder Investment Management Group Has $17.37 Million Position in Repligen Co. (RGEN)” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://ledgergazette.com/2017/12/06/schroder-investment-management-group-has-17-37-million-position-in-repligen-co-rgen.html.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply